Selected Presentations
Session I: Basic Mechanisms of HIV Latency
The NCOR2-Nurr1-CoREST Transrepression Axis Impairs HIV Reactivation in Latently Infected Microglial Cells
David Alvarez-Carbonell; Case Western Reserve University, Cleveland, USA
Session II: Assays to Measure HIV Persistence
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
Janet Siliciano; John Hopkins University, Baltimore, USA
Assessment and Quantification of Cell Associate Unspliced HIV-1 RNA using Reverse Transcriptase Droplet Digital PCR
Zixin Hu; Brigham and Woman’s Hospital and Harvard Medical School, Cambridge, USA
Droplet Digital PCR, the new tool in HIV reservoir quantification?
Ward De Spiegelaere; Ghent University, Ghent, Beligum
Comparison of Latent HIV-1 Reactivation in Multiple Cell Models and Resting CD4+ T Cells from Aviremic Patients
Vicente Planelles; University of Utah, Salt Lake City, USA
Session III: In vivo and in vitro Models of HIV Persistence
Viral Reservoirs and Anti-Latency Interventions in Nonhuman Primate Models of SIV/SHIV Infection
Koen VanRompay; UC Davis, Davis, USA
Session V: Anatomic and non-CD4 Cell Reservoirs
Distribution and Fine Structure Genetic Analysis of HIV in Gut Associated Lymphoid Tissue (GALT) and Blood after Prolonged Antiretroviral Therapy
Francesco Simonetti; NCI-NIH; Frederick, USA
Session VI: Immunology of HIV Persistence
The Role of Immune-based Therapeutics in Curing HIV Infection
Steven Deeks; University of California San Francisco, San Francisco, USA
Low Tryptophan 2,3-dioxegenase (TDO) Expression is Associated with Distinctive Immune-metabolism of Tryptophan and Preserved Th17/Treg Balance in HIV Elite Controllers
Jean-Pierre Routy; McGill University Health Centre, Montreal, Canada
Session VII: Pharmacology of HIV Persistence
What If a Drug that was Developed to Treat HIV Infection Could Actually Help to Cure It?
Mark Wainberg; McGill University AIDS Centre, Montreal, Canada
Session IX: Drug Discovery
Dual Approach to HIV-1 Cure: Activation of Latency and Restoration of Exhausted Virus-specific T Cell Function
Steve Mason; Bristol Myers Squibb, New York, USA
Session X: Acute HIV Infection and Functional Cure
Sigmoid Lamina Propria CD4 T cell Depletion during Acute HIV Infection is Associated with Activated CD4/CD8 T cells, Inflammatory Biomarkers and Viral Burden in the Gut and Blood
Jintanat Ananworanich; SEARCH, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
Session XII: New Therapeutic Approaches – Part II
Immune Activation and HIV Persistence: New Therapeutic Approaches
Hiroyu Hatano; University of California, San Francisco, USA
Update in HIV Therapeutic Vaccines and Immunotherapy
Jose Gatell; Hospital Clinic, Barcelona, Spain
Ing-B (ingenol-3-hexanoate) is a Potential PKC Activator for the Shock and Kill Strategy in HIV Eradication
Lucio Gama; Johns Hopkins School of Medicine, Baltimore, USA
